logo
Plus   Neg
Share
Email

Axsome Reports Positive Results From Phase 3 Trial Of AXS-07 In Acute Treatment Of Migraine

Axsome Therapeutics Inc. (AXSM) announced positive efficacy and safety results from phase 3 movement long-term trial of AXS-07 in the acute treatment of migraine.

According to the company, treatment with AXS-07, rapidly, substantially, and durably relieved migraine pain and associated symptoms in this trial. AXS-07 was well tolerated over long-term treatment with a safety profile consistent with that observed in the previously reported controlled trials.

Two hours after administration of AXS-07, relief of migraine pain was achieved by 68% of patients and pain freedom by 38% of patients.

AXS-07 durably relieved migraine pain with 85% of patients free from rescue medication use through 24 hours, and 83% of patients free from rescue medication use through 48 hours after a single administration of AXS-07.

AXS-07 was well tolerated with long-term dosing. The safety profile of AXS-07 over the 12-month treatment period was consistent with that previously reported in short-term controlled trials.

Axsome said it remains on track to submit an new drug application or NDA for AXS-07 in the acute treatment of migraine in the first quarter of 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The United Kingdom's Competition and Markets Authority (CMA) has launched an investigation into technology giant Apple Inc. (AAPL) following complaints that its terms and conditions for app developers are unfair and anti-competitive. iPhone maker Apple also operates the App Store, which is the only... Supermarket chain Kroger Co. on Thursday reported that it posted a loss for the fourth quarter compared to a profit last year, hurt by pension plan withdrawal liabilities. Adjusted earnings per share topped analysts' estimates, while quarterly revenues missed it. However, the company initiated adjusted earning guidance for the full-year 2021, well above analysts' estimates. Retail sales are projected to grow at a potentially record rate during 2021, but the ongoing COVID-19 pandemic remains the biggest challenge for the year, according to the National Retail Federation. "There is no doubt the economy is positioned for growth in 2021, but how much growth comes down to a single non-economic force - the coronavirus," NRF Chief Economist Jack Kleinhenz said.
Follow RTT